Skip to content

US · IRWD · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Ironwood Pharmaceuticals, Inc. (IRWD) intrinsic value and stock valuation

$4.70as of 2026-11-21 · Mkt cap 683.14M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ironwood Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values IRWD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IRWD’s statements →

Ironwood Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Boston, MA 02110 ironwoodpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$296.2M-5.3% 5y CAGRd
20112025
Net income
$24M-25.7% 5y CAGRd
20112025
Free cash flow
$127M-5.3% 5y CAGRd
20112025
Total equity
-$-261.83M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$296.2M$351.4M$442.7M$410.6M$413.8M
Operating income$118.8M$93.1M-$-945.43M$250.3M$232.3M
Net income$24M$880K-$-1B$175.1M$528.5M
EPSd$135.1K$5.5K-$-6.45M$939.6K$3.21M
Operating cash flow$127M$103.6M$183.4M$273.8M$261.9M
Capital expenditure-$-30K-$-140K-$-270K-$-140K-$-270K
Free cash flow$127M$103.4M$183.2M$273.6M$261.6M
Total assets$396.9M$350.9M$471.1M$1.1B$1.13B
Total debt$597.8M$599.5M$715.5M$415.9M$475.8M
Net debt$382.4M$510.9M$623.4M-$-240.29M-$-144.33M
Total equity-$-261.83M-$-301.33M-$-346.3M$652.4M$605.9M
Cash and short-term investments$215.5M$88.6M$92.2M$656.2M$620.1M
Income statement
20252024202320222021
Revenue$296.2M$351.4M$442.7M$410.6M$413.8M
Cost of revenue$0.00$7.55M$6.15M$1.42M$70.4M
Gross profit$296.2M$343.9M$436.6M$409.2M$343.4M
Research and development expenses$95.1M$111.4M$116.1M$44.3M$70.4M
Selling, general and administrative expenses$82.3M$0.00$0.00$116M$0.00
Other expenses$0.00$139.3M$1.27B-$-1.42M$40.7M
Operating expenses$177.4M$250.7M$1.38B$158.8M$111.1M
Cost and expenses$177.4M$258.3M$1.39B$160.3M$181.5M
Interest income$4.08M$4.47M$19M$9.5M$730K
Interest expense$32.8M$33M$21.6M$7.6M$31.2M
Depreciation and amortization$1.88M$2.01M$1.57M$1.42M$1.52M
Ebitda$104.7M$97.7M$197.4M$261.4M$233.7M
Operating income$118.8M$93.1M-$-945.43M$250.3M$232.3M
Total other income/expenses, net-$-48.73M-$-27.93M-$-2.64M$2.08M-$-31.6M
Income before tax$70M$65.2M-$-948.07M$252.4M$200.7M
Income tax expense$46M$64.3M$83.5M$77.4M-$-327.79M
Net income$24M$880K-$-1B$175.1M$528.5M
Weighted average shares outstanding$162.2M$159.1M$155.4M$154.4M$162.3M
Weighted average diluted shares outstanding$177.8M$160.1M$155.4M$186.3M$164.4M
Balance sheet
20252024202320222021
Cash and short-term investments$215.5M$88.6M$92.2M$656.2M$620.1M
Net receivables$46.7M$81.9M$129.1M$115.5M$114M
Inventory$0.00$0.00$0.00$1.25M$0.00
Total current assets$274.2M$182.4M$233.3M$780.6M$745.2M
Property, plant and equipment, net$12.8M$15.5M$18.2M$20.3M$22.9M
Goodwill and intangible assets$2.04M$2.86M$3.68M$0.00$0.00
Long-term investments$0.00$0.00$0.00$15.1M$0.00
Total non-current assets$122.7M$168.5M$237.8M$319.9M$381.7M
Total assets$396.9M$350.9M$471.1M$1.1B$1.13B
Accounts payable$2.9M$2.13M$7.83M$480K$940K
Short-term debt$202.9M$3.19M$202.7M$3.06M$120M
Deferred revenue$1.11M$2.03M$2.62M$0.00$0.00
Total current liabilities$242.2M$38.9M$276.1M$25.5M$161.7M
Long-term debt$394.9M$596.3M$512.9M$412.9M$355.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$416.5M$613.4M$541.3M$422.6M$359.3M
Capital lease obligations$13.1M$15.5M$17.7M$19.7M$21.6M
Total liabilities$658.7M$652.2M$817.4M$448.1M$521M
Common stock$160K$160K$160K$150K$160K
Retained earnings-$-1.67B-$-1.7B-$-1.7B-$-696.38M-$-937.61M
Accumulated other comprehensive income (loss)-$-1.06M$920K-$-3.03M$0.00-$0.00
Total equity-$-261.83M-$-301.33M-$-346.3M$652.4M$605.9M
Total investments$0.00$0.00$0.00$15.1M$0.00
Total debt$597.8M$599.5M$715.5M$415.9M$475.8M
Net debt$382.4M$510.9M$623.4M-$-240.29M-$-144.33M
Cash flow statement
20252024202320222021
Net income$24M$880K-$-1B$175.1M$528.5M
Depreciation and amortization$1.88M$2.01M$1.57M$1.42M$1.5M
Stock-based compensation$17.3M$29.9M$32M$27.1M$22.3M
Change in working capital$39.7M$740K$11.3M$2.82M$17.7M
Accounts receivable$35.2M$47.2M$920K$7.99M$7.71M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$6.2M-$-20.21M$12.4M-$-8.12M-$-2.64M
Net cash provided by operating activities$127M$103.6M$183.4M$273.8M$261.9M
Investments in property, plant and equipment-$-30K-$-140K-$-270K-$-140K-$-270K
Acquisitions, net$0.00$0.00-$-1.03B$0.00$0.00
Net cash used for investing activities-$-30K-$-140K-$-1.03B-$-140K-$-270K
Common stock issued$220K$11M$6.36M$9.54M$19.6M
Common stock repurchased$0.00$0.00$0.00-$-126.39M-$-24.13M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$220K-$-106.97M$277.2M-$-237.55M-$-4.55M
Net change in cash$126.9M-$-3.6M-$-565.78M$36.1M$257.1M
Cash at end of period$215.5M$88.6M$92.2M$657.9M$621.9M
Operating cash flow$127M$103.6M$183.4M$273.8M$261.9M
Capital expenditure-$-30K-$-140K-$-270K-$-140K-$-270K
Free cash flow$127M$103.4M$183.2M$273.6M$261.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ironwood Pharmaceuticals, Inc.

        Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.

        CEO
        Thomas A. McCourt
        Employees
        100
        Beta
        0.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Ironwood Pharmaceuticals, Inc. (IRWD)?

        Ironwood Pharmaceuticals, Inc. (IRWD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IRWD undervalued?

        IRWD trades at a price of $4.70 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.